Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Follicular 3Lymphoma 3Lymphoma, Non-Hodgkin 2Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Multiple Myeloma 1Melanoma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Influenza, Human 1Epstein-Barr Virus Infections 1Breast Neoplasms 1Blast Crisis 1

Interventions

Influenza Vaccines 3trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine 2vaxigrip 1thymoglobulin 1peginterferon alfa-2a 1influvac 1fludarabine 1Vaccines 1Starch 1SARS-CoV-2 inactivated vaccines 1Rituximab 1Oseltamivir 1Melphalan 1Levetiracetam 1Lenalidomide 1Interferons 1Interferon alpha-2 1Cyclophosphamide 1Celecoxib 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Influenza, Human × Interferons × Lymphoid × Clear all
NCT00962715 2012-08-03

Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Influenza, Human, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡